Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ATNM NASDAQ:EPRX NASDAQ:GNFT NASDAQ:TLSA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATNMActinium Pharmaceuticals$1.63+0.6%$1.65$1.03▼$2.41$50.85M-0.3388,197 shs23,710 shsEPRXEupraxia Pharmaceuticals$5.28-0.8%$5.35$2.20▼$6.20$189.87M1.4912,526 shs4,277 shsGNFTGENFIT$4.33-0.1%$3.96$2.55▼$6.42$216.31M1.168,147 shs2,264 shsTLSATiziana Life Sciences$1.69-0.6%$1.86$0.63▼$2.60$197.47M-0.36578,787 shs61,893 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATNMActinium Pharmaceuticals-0.61%+1.25%-4.14%+13.29%-12.90%EPRXEupraxia Pharmaceuticals-0.56%+0.57%-0.38%+24.12%+105.43%GNFTGENFIT+1.43%+7.60%+6.79%+3.55%+3.93%TLSATiziana Life Sciences+0.59%+4.94%-13.71%+3.03%+83.80%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATNMActinium Pharmaceuticals$1.63+0.6%$1.65$1.03▼$2.41$50.85M-0.3388,197 shs23,710 shsEPRXEupraxia Pharmaceuticals$5.28-0.8%$5.35$2.20▼$6.20$189.87M1.4912,526 shs4,277 shsGNFTGENFIT$4.33-0.1%$3.96$2.55▼$6.42$216.31M1.168,147 shs2,264 shsTLSATiziana Life Sciences$1.69-0.6%$1.86$0.63▼$2.60$197.47M-0.36578,787 shs61,893 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATNMActinium Pharmaceuticals-0.61%+1.25%-4.14%+13.29%-12.90%EPRXEupraxia Pharmaceuticals-0.56%+0.57%-0.38%+24.12%+105.43%GNFTGENFIT+1.43%+7.60%+6.79%+3.55%+3.93%TLSATiziana Life Sciences+0.59%+4.94%-13.71%+3.03%+83.80%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATNMActinium Pharmaceuticals 3.00Buy$4.50177.78% UpsideEPRXEupraxia Pharmaceuticals 3.17Buy$11.00107.55% UpsideGNFTGENFIT 3.00Buy$9.00111.22% UpsideTLSATiziana Life Sciences 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ATNM, GNFT, TLSA, and EPRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/20/2025EPRXEupraxia PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.008/19/2025GNFTGENFITHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$9.007/24/2025EPRXEupraxia PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$11.006/26/2025EPRXEupraxia PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$12.006/26/2025EPRXEupraxia PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$12.006/24/2025ATNMActinium PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$4.006/16/2025EPRXEupraxia PharmaceuticalsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageSpeculative Buy(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATNMActinium PharmaceuticalsN/AN/AN/AN/A$1.31 per shareN/AEPRXEupraxia PharmaceuticalsN/AN/AN/AN/AN/AN/AGNFTGENFIT$67.00M3.18$0.07 per share60.73$1.50 per share2.84TLSATiziana Life SciencesN/AN/AN/AN/A$0.04 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATNMActinium Pharmaceuticals-$48.82M-$1.31N/AN/AN/AN/A-100.85%-47.89%N/AEPRXEupraxia Pharmaceuticals-$25.50M-$0.85N/AN/AN/AN/A-626.84%-118.31%11/6/2025 (Estimated)GNFTGENFIT$1.63MN/A0.00N/AN/AN/AN/AN/A9/22/2025 (Estimated)TLSATiziana Life Sciences-$11.86MN/A0.00∞N/AN/AN/AN/A10/13/2025 (Estimated)Latest ATNM, GNFT, TLSA, and EPRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025EPRXEupraxia Pharmaceuticals-$0.21-$0.26-$0.05-$0.26N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATNMActinium PharmaceuticalsN/AN/AN/AN/AN/AEPRXEupraxia PharmaceuticalsN/AN/AN/AN/AN/AGNFTGENFITN/AN/AN/AN/AN/ATLSATiziana Life SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATNMActinium PharmaceuticalsN/A10.2510.25EPRXEupraxia PharmaceuticalsN/A8.728.72GNFTGENFIT0.081.231.23TLSATiziana Life SciencesN/A1.021.02Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATNMActinium Pharmaceuticals27.50%EPRXEupraxia PharmaceuticalsN/AGNFTGENFIT2.24%TLSATiziana Life SciencesN/AInsider OwnershipCompanyInsider OwnershipATNMActinium Pharmaceuticals6.00%EPRXEupraxia PharmaceuticalsN/AGNFTGENFIT4.20%TLSATiziana Life Sciences39.82%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATNMActinium Pharmaceuticals3031.20 million29.32 millionOptionableEPRXEupraxia Pharmaceuticals2935.96 millionN/AN/AGNFTGENFIT12050.00 million47.90 millionNot OptionableTLSATiziana Life Sciences8116.85 million70.32 millionOptionableATNM, GNFT, TLSA, and EPRX HeadlinesRecent News About These CompaniesTiziana Life Sciences announces U.S. DoD awarded research grant to study SCISeptember 15 at 2:33 PM | msn.comTiziana Life Sciences Secures DoD Grant for Spinal Cord Injury ResearchSeptember 15 at 2:33 PM | msn.comTiziana Life Sciences awarded DoD grant to advance intranasal therapy for spinal cord injurySeptember 15 at 9:24 AM | proactiveinvestors.comDepartment of Defense Awards Grant to Advance Tiziana Life Sciences Intranasal Anti-CD3 Therapy for Spinal Cord InjurySeptember 15 at 8:00 AM | globenewswire.comTiziana Life Sciences reports CEO purchased 14,848 sharesSeptember 10, 2025 | msn.comTiziana Life Sciences Announces Purchase of Shares by Chief Executive OfficerSeptember 9, 2025 | globenewswire.comTiziana Life Sciences Announces Purchase of Shares by Chief Executive OfficerSeptember 9, 2025 | globenewswire.comTiziana Life Sciences Announces Purchase of Shares by ChairmanSeptember 5, 2025 | globenewswire.comTiziana Life Sciences Ltd's (NASDAQ:TLSA) largest shareholders are retail investors with 53% ownership, insiders own 43%September 1, 2025 | finance.yahoo.comTiziana Life Sciences (NASDAQ:TLSA) Trading Down 7.4% - Time to Sell?August 21, 2025 | marketbeat.comTiziana Life Sciences doses first MSA patient in new trial – ICYMIAugust 15, 2025 | proactiveinvestors.comTiziana Life Sciences Initiates Phase 2a Trial for MSA with Intranasal ForalumabAugust 14, 2025 | msn.comTiziana Life doses first patient in Phase 2a trial of intranasal foralumabAugust 14, 2025 | msn.comTiziana Life Sciences doses first patient in Phase 2a MSA trialAugust 14, 2025 | proactiveinvestors.comTiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab for Multiple System AtrophyAugust 14, 2025 | globenewswire.comTiziana Life Sciences Phase 2a multiple system atrophy study green-lit by FDAAugust 11, 2025 | proactiveinvestors.comFDA Approves Tiziana Life Sciences Phase 2 IND for Multiple System AtrophyAugust 11, 2025 | globenewswire.comTiziana Life Sciences reports encouraging results from nasal Alzheimer's treatmentJuly 21, 2025 | proactiveinvestors.comTiziana Life Sciences Announces Immunologic Analysis of Nasal Foralumab in Moderate Alzheimer's PatientJuly 21, 2025 | globenewswire.comTiziana Life Sciences Ltd (TLSA) - Yahoo FinanceJuly 11, 2025 | finance.yahoo.comTiziana: Scope Of Foralumab Goes Beyond That Of Multiple Sclerosis TargetingJune 13, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeATNM, GNFT, TLSA, and EPRX Company DescriptionsActinium Pharmaceuticals NYSE:ATNM$1.63 +0.01 (+0.62%) As of 10:29 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.Eupraxia Pharmaceuticals NASDAQ:EPRX$5.28 -0.04 (-0.75%) As of 10:26 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC.GENFIT NASDAQ:GNFT$4.33 0.00 (-0.09%) As of 09:56 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.Tiziana Life Sciences NASDAQ:TLSA$1.69 -0.01 (-0.59%) As of 10:29 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Why Opendoor Stock Is Soaring—and May Just Be Starting Reddit Hits Record Highs: Why Wall Street Is Taking Notice Royal Caribbean's 33% Dividend Hike Signals Deeper Growth Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
